On the filings, Becton Dickinson (BDX) is the stronger stock right now — higher on our blended fundamentals-plus-verdict read, and we currently rate it HOLD.
Durable medtech franchise with growing revenue but stalled earnings, a 6.6% ROE and full 24.7x multiple — own it, don't chase.
Baxter posted a second straight operating loss, slashed its dividend 41% and carries $9.44B debt — cheap, but the fundamentals are deteriorating.
| Metric | BDX | BAX |
|---|---|---|
| Fundamentals score | 64 | 37 |
| Revenue growth (YoY) | +8.2% | +5.7% |
| Net income growth (YoY) | -1.6% | -47.5% |
| Net margin | 7.7% | -8.5% |
| Return on equity | 6.6% | -15.6% |
| ROIC (est.) | 4.6% | -1.6% |
| Liabilities / Equity | — | 2.28 |
| Piotroski F-score | 6 / 9 | 5 / 9 |
Bold green = the stronger figure. All rows derive from SEC XBRL filings — no market-price data on this page.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 12:33 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:50 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.